-

11:00:19 AM

AVDL Stock News

AVDL - Avadel Pharmaceuticals plc

03/10/23 11:40 AM

Nasdaq : AVDL

Global Nanobiotechnology Market to Reach $160.3 Billion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Fears of new COVID outbreaks and China's already...

RHEA-AI

neutral

03/02/23 7:00 AM

Nasdaq : AVDL

fda approval

Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it has

RHEA-AI

neutral

02/16/23 4:05 PM

Nasdaq : AVDL

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new

RHEA-AI

very positive

02/08/23 8:00 AM

Nasdaq : AVDL

conferences

Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma

RHEA-AI

neutral

02/03/23 8:00 AM

Nasdaq : AVDL

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new

RHEA-AI

very positive

01/24/23 8:00 AM

Nasdaq : AVDL

Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on

RHEA-AI

very negative

01/23/23 4:05 PM

Nasdaq : AVDL

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new

RHEA-AI

very positive

01/10/23 4:05 PM

Nasdaq : AVDL

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new

RHEA-AI

neutral

01/09/23 9:00 AM

Nasdaq : ACAD, AVDL

management

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. announced today the appointment of Dr. Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’ s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr.

RHEA-AI

very positive

12/01/22 4:05 PM

Nasdaq : AVDL

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one (1) new

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next